Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
10:00am, Tuesday, 14'th May 2024
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel the
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
08:00am, Wednesday, 08'th May 2024
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and comm
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
08:00am, Tuesday, 05'th Mar 2024
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel t
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
04:01pm, Wednesday, 28'th Feb 2024
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Wednesday, 28'th Feb 2024
Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that mad
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
10:56am, Wednesday, 21'st Feb 2024
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 35.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
09:51am, Monday, 12'th Feb 2024
Keros Therapeutics, Inc. (KROS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
10:56am, Wednesday, 31'st Jan 2024
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
08:00am, Monday, 29'th Jan 2024
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
09:50am, Wednesday, 24'th Jan 2024
Keros Therapeutics, Inc. (KROS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that pass
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Tuesday, 23'rd Jan 2024
From a technical perspective, Keros Therapeutics, Inc. (KROS) is looking like an interesting pick, as it just reached a key level of support. KROS's 50-day simple moving average crossed above its 200-
How Much Upside is Left in Keros Therapeutics, Inc. (KROS)? Wall Street Analysts Think 57.46%
11:17am, Monday, 15'th Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 57.5% in Keros Therapeutics, Inc. (KROS). While the effectiveness of this highly sought-after metric is questio
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
08:00am, Tuesday, 09'th Jan 2024
LEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
09:29pm, Wednesday, 03'rd Jan 2024
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ
Keros Therapeutics Announces Proposed Public Offering of Common Stock
04:05pm, Wednesday, 03'rd Jan 2024
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel th
